Similar articles

• Lenacapavir: A novel injectable HIV-1 capsid inhibitor.

  Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Hitchcock AM, et al. Int J Antimicrob Agents. 2024 Jan;63(1):107009. doi: 10.1016/j.ijantimicag.2023.107009. Epub 2023 Oct 14. Int J Antimicrob Agents. 2024. PMID: 37844807 Review.
• Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.

  Prather C, Lee A, Yen C. Prather C, et al. Am J Health Syst Pharm. 2023 Dec 5;80(24):1774-1780. doi: 10.1093/ajhp/zxad223. Am J Health Syst Pharm. 2023. PMID: 37767713 Review.
• Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.

  Tuan J, Ogbuagu O. Tuan J, et al. Expert Rev Anti Infect Ther. 2023 Jun;21(6):565-570. doi: 10.1080/14787210.2023.2203913. Epub 2023 Apr 20. Expert Rev Anti Infect Ther. 2023. PMID: 37067160 Review.
• Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.

  Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, Dumond JB, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, Pérez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Cluck DB, et al. Pharmacotherapy. 2024 May;44(5):360-382. doi: 10.1002/phar.2914. Pharmacotherapy. 2024. PMID: 38853601 Review.
• Lenacapavir: First Approval.

  Paik J. Paik J. Drugs. 2022 Sep;82(14):1499-1504. doi: 10.1007/s40265-022-01786-0. Drugs. 2022. PMID: 36272024 Free PMC article. Review.